Anti-interferon alpha monoclonal antibodies and methods for use

A method of neutralizing at least one IFNα protein subtype in the blood of a subject, wherein the IFNα protein subtype is selected from the group consisting of protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, and wherein said method comprises administering to said subject an effective amount of an antibody selected from the group consisting of:

• a) an anti-interferon alpha antibody produced by the hybridoma deposited with the ATCC as Accession No. PTA-6557;
• b) a humanized antibody that is a humanized form of the anti-interferon alpha antibody produced by the hybridoma deposited with the ATCC as Accession No. PTA-6557;
• c) a humanized antibody that is a humanized form of the antibody ACO-1;
• d) a humanized antibody that is an antibody fragment of a humanized form of the anti-interferon alpha antibody produced by the hybridoma deposited with the ATCC as Accession No. PTA-6557, wherein the antibody fragment specifically neutralizes a bioactivity of at least ten interferon alpha protein subtypes selected from the group consisting of IFNα protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not significantly neutralize said bioactivity of IFNα protein subtype D, wherein said bioactivity is activation of the MxA promoter or antiviral activity;
• e) the humanized antibody of (d) that is an Fab, Fab′, F(ab′)2, Fv or sFv fragment;
• f) an antibody comprising at least one light chain that comprises the CDRs:
• VL1 having the amino acid sequence of SEQ ID NO:12;
• VL2 having the amino acid sequence of SEQ ID NO:14;
• and
• VL3 having the amino acid sequence of SEQ ID NO:16;
• and
• at least one heavy chain that comprises the CDRs:
• VH1 having the amino acid sequence of SEQ ID NO:4;
• VH2 having the amino acid sequence of SEQ ID NO:6;
• VH3 having the amino acid sequence of SEQ ID NO:8;
• and
• g) the antibody of any of (a) through (f) that is an IgG4 isotype antibody,
• wherein said subject has a disease or condition that is AIDS, and wherein at least IFNα protein subtype in the blood of said subject is neutralized.